PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för apremilast. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

23 hits

Bibliografisk träff 2014-11-01

The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers.

Liu Y, Zhou S, Wan Y, Wu A, Palmisano M.

Br J Clin Pharmacol · clinical trial; research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/bcp.12448

Bibliografisk träff 2014-09-01

An oral phosphodiesterase inhibitor (apremilast) for inflammatory rosacea in adults: a pilot study.

Thompson BJ, Furniss M, Zhao W, Chakraborty B, Mackay-Wiggan J.

JAMA Dermatol · research support, non-u.s. gov't; journal article · DOI 10.1001/jamadermatol.2013.10526

Bibliografisk träff 2014-07-02

Current treatment of psoriatic arthritis: update based on a systematic literature review to establish French Society for Rheumatology (SFR) recommendations for managing spondyloarthritis.

Paccou J, Wendling D.

Joint Bone Spine · systematic review; journal article · DOI 10.1016/j.jbspin.2014.05.003

Bibliografisk träff 2014-06-01

Pharmaceutical approval update.

Goldenberg MM.

P T · other; journal article

Bibliografisk träff 2014-05-29

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.

Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, Man HW, Muller GW, Stirling DI, Chopra R.

Cell Signal · research support, non-u.s. gov't; journal article · DOI 10.1016/j.cellsig.2014.05.014

Bibliografisk träff 2014-05-20

Spondyloarthropathies: Apremilast: welcome advance in treatment of psoriatic arthritis.

FitzGerald O.

Nat Rev Rheumatol · news · DOI 10.1038/nrrheum.2014.77

Bibliografisk träff 2014-05-16

A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology.

Moustafa F, Feldman SR.

Dermatol Online J · review; journal article · DOI 10.5070/d3205022608

Bibliografisk träff 2014-05-01

Apremilast: first global approval.

Poole RM, Ballantyne AD.

Drugs · review; journal article · DOI 10.1007/s40265-014-0218-4

Bibliografisk träff 2014-05-01

Apremilast (otezla) for psoriatic arthritis.

Författaruppgift saknas

Med Lett Drugs Ther · letter; review

Bibliografisk träff 2014-05-01

[Progress in PDE4 targeted therapy for inflammatory diseases].

Song SD, Tang HF.

Zhejiang Da Xue Xue Bao Yi Xue Ban · research support, non-u.s. gov't; review; journal article; english abstract · DOI 10.3785/j.issn.1008-9292.2014.05.015

Bibliografisk träff 2014-04-04

Apremilast for the treatment of psoriatic arthritis.

Varada S, Tintle SJ, Gottlieb AB.

Expert Rev Clin Pharmacol · review; journal article · DOI 10.1586/17512433.2014.904200

Bibliografisk träff 2014-03-04

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Lespessailles E, Hall S, Hochfeld M, Hu C, Hough D, Stevens RM, Schett G.

Ann Rheum Dis · clinical trial, phase iii; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1136/annrheumdis-2013-205056

Bibliografisk träff 2014-03-01

New and emerging therapies in psoriasis.

Leonardi CL, Gordon KB.

Semin Cutan Med Surg · journal article · DOI 10.12788/j.sder.0066

Bibliografisk träff 2014-01-02

Advances in treating psoriasis.

Belge K, Brück J, Ghoreschi K.

F1000Prime Rep · review-article; review; journal article · DOI 10.12703/p6-4

Bibliografisk träff 2014-01-01

Novel treatments with small molecules in psoriatic arthritis.

Hansen RB, Kavanaugh A.

Curr Rheumatol Rep · review; journal article · DOI 10.1007/s11926-014-0443-6

Bibliografisk träff 2013-09-26

Proposal for a new nomenclature of disease-modifying antirheumatic drugs.

Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewé R.

Ann Rheum Dis · journal article · DOI 10.1136/annrheumdis-2013-204317

Bibliografisk träff 2013-08-01

Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.

Gottlieb AB, Matheson RT, Menter A, Leonardi CL, Day RM, Hu C, Schafer PH, Krueger JG.

J Drugs Dermatol · clinical trial, phase ii; multicenter study; journal article

Bibliografisk träff 2013-05-10

Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study.

Strand V, Fiorentino D, Hu C, Day RM, Stevens RM, Papp KA.

Health Qual Life Outcomes · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1186/1477-7525-11-82

Bibliografisk träff 2013-04-15

Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study.

Strand V, Schett G, Hu C, Stevens RM.

J Rheumatol · clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.3899/jrheum.121200

Bibliografisk träff 2013-03-27

New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.

Palfreeman AC, McNamee KE, McCann FE.

Drug Des Devel Ther · review-article; review; journal article · DOI 10.2147/dddt.s32713

Bibliografisk träff 2012-10-03

Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.

Papp KA, Kaufmann R, Thaçi D, Hu C, Sutherland D, Rohane P.

J Eur Acad Dermatol Venereol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1111/j.1468-3083.2012.04716.x

Bibliografisk träff 2012-09-14

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis.

Pathan E, Abraham S, Van Rossen E, Withrington R, Keat A, Charles PJ, Paterson E, Chowdhury M, McClinton C, Taylor PC.

Ann Rheum Dis · clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1136/annrheumdis-2012-201915

Bibliografisk träff 2012-08-19

An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: a case series.

Paul J, Foss CE, Hirano SA, Cunningham TD, Pariser DM.

J Am Acad Dermatol · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1016/j.jaad.2012.07.014